Flecainide inhalation - InCarda Therapeutics

Drug Profile

Flecainide inhalation - InCarda Therapeutics

Alternative Names: Inhaled flecainide - InCarda Therapeutics; InRhythm™

Latest Information Update: 28 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator InCarda Therapeutics
  • Class Class Ic antiarrhythmics; Piperidines; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Paroxysmal atrial fibrillation

Most Recent Events

  • 11 Nov 2017 Safety, pharmacokinetics and pharmacodynamics data from a phase I trial in healthy volunteers presented at the 90th Annual Scientific Sessions of the American Heart Association (AHA-2017)
  • 09 Aug 2017 InCarda Therapeutics completes a phase I trial in Paroxysmal atrial fibrillation (In volunteers) in Australia (ACTRN12616001156471)
  • 07 Jun 2017 Pharmacokinetics data from a phase I trial in Paroxysmal atrial fibrillation released by InCarda Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top